This is a prospective, multi-centre randomised trial comparing between ERBT plus 1-year of Ad-MMC, versus ERBT alone, in treating intermediate-risk NMIBC.
Conditions: Bladder Cancer
Eligibility Criteria
Inclusion Criteria
- Age ≥ 18 years old with informed consent
- ERBT was successfully performed with clear resection margins
- Histologically confirmed intermediate-risk NMIBC
- Patients who are ineligible or refused to undergo intravesical BCG therapy
Exclusion Criteria
- Any prior use of intravesical induction and/or maintenance chemotherapy instillations
- Any prior use of intravesical BCG therapy
- Presence or prior history of upper urinary tract malignancy
- Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (20)
- Presence of GOLD Stage III or IV chronic obstructive pulmonary disease (21)
- ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities)
- Pregnancy
- Presence of other active malignancy
Eligibility criteria are kept as the original English records from ClinicalTrials.gov; actual eligibility is determined by the research team's formal assessment and the informed consent form. Source: ClinicalTrials.gov, updated automatically every two weeks. Last synced: 2026年11月5日.